Vyant Bio, Inc., an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system diseases.
Cherry Hill, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) diseases. Today, Vyant Bio announced that it will be participating in the H.C. Wainwright Bioconnect Conference. The event is being held virtually from January 10-13, 2022. Registered attendees can access the recorded presentation on-demand (24x7) for the duration of the conference.
| Conference Date: | January10-13, 2022 (Monday-Thursday) |
| On-Demand Starts: | 7:00am ET - Monday, January10, 2022 |
| On-Demand Ends: | 7:00pm ET- Thursday, January, 13, 2022 |
| Registration: | https://hcwevents.com/bioconnect/ |
During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts, and Chief Scientific Officer, Robert Fremeau, Ph.D., will be discussing key highlights from 2021 and the scientific, business and strategic outlook for 2022. The presentation will be an archived recording will be made available in the Investors’ section of the Vyant Bio website.
If you are an institutional investor and would like to participate in this event please, click on the following link (https://hcwevents.com/bioconnect/) to register for the H.C. Wainwright Bioconnect Conference. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company.
Vyant Bio will also be available for virtual outside 1:1 meetings after the H.C. Wainwright Bioconnect Conference. Please contact Jennifer K. Zimmons, Ph.D. at jzimmons@zimmonsic.com or +1 917.214.3514 for scheduling.
ABOUT VYANT BIO, INC.
Vyant Bio is discovering neurological developmental and degenerative disease therapeutics, accelerated by its unique drug discovery engine centered on revolutionary human-derived biology that incorporates advanced technology driven chemistry, data science, and engineering with global regulatory expertise. Through multiple in silico, in vitro, and in vivo modalities, Vyant Bio’s world-renowned scientific team rapidly identifies and designs small and large molecule therapeutics that are derisked in human biology much earlier, and have lower costs and failure rates compared to traditional discovery platforms. The Company is focused on efficiently discovering central nervous system drugs and, going forward, plans to file two investigational new drug applications annually. Vyant Bio is headquartered in the US, with offices in Europe, and research facilities in Australia.
For more information, please visit or follow Vyant Bio at:
Internet: www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability and increase sales of our services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger of StemoniX, Inc. and Cancer Genetics, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.
Investor Contacts:
Jennifer K. Zimmons, Ph.D., MBA
Investor Relations
Zimmons International Communications, Inc.
Email: jzimmons@zimmonsic.com
Phone: +1.917.214.3514
###
